SCHEMBL788248

SCHEMBL788248

Cn1c(=O)c(O)nc2c(Cl)ncnc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
MAPT P10636 1/20 0.38
KDM4E B2RXH2 2/20 0.37
HPGD P15428 2/20 0.37
JAK2 O60674 1/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
PAX8 Q06710 1/20 0.37
CYP1A2 P05177 3/20 0.36
TSHR P16473 2/20 0.36
USP2 O75604 1/20 0.36
ADORA2A P29274 3/20 0.35
ADORA1 P30542 3/20 0.35
ADORA2B P29275 2/20 0.35
FDPS P14324 1/20 0.35
P2RX7 Q99572 2/20 0.33
CYP2C9 P11712 1/20 0.33
HSD17B10 Q99714 1/20 0.33
FBP1 P09467 1/20 0.32
FGFR1 P11362 5/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9740432 0.80 ADORA2A (0.39) ALDH1A1MAPTKDM4EHPGDJAK2
SCHEMBL788188 0.78 ALDH1A1 (0.38) ALDH1A1MAPTKDM4EHPGDJAK2
SCHEMBL15718948 0.76 PIK3CD (0.41) ALDH1A1MAPTKDM4EHPGDJAK2
SCHEMBL9739976 0.74 ADORA2A (0.40) ALDH1A1MAPTKDM4EHPGDJAK2
SCHEMBL31065821 0.73 ADORA2A (0.64) ADORA2AADORA1ADORA2BADORA3PI4KA
SCHEMBL788330 0.73 ADORA2A (0.64) ADORA2AADORA1ADORA2BADORA3PI4KA
SCHEMBL24672007 0.71 SLC22A12 (0.39) ALDH1A1MAPTHPGDLMNAHTT
SCHEMBL4067321 0.71 ADORA3 (0.57) ALDH1A1ADORA2AADORA1ADORA2BADORA3
SCHEMBL15718693 0.70 CSNK2A2 (0.39) ALDH1A1MAPTHTTCYP1A2TSHR
SCHEMBL4064370 0.70 ADORA1 (0.60) ADORA2AADORA1ADORA2BP2RX7ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616469-B1 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE EXELIXIS INC (US) 2016-10-26 EP disclosed
US-9346807-B2 Inhibitors of PI3K-delta and methods of their use and manufacture EXELIXIS, INC. (US) 2016-05-24 US disclosed
US-20140058103-A1 Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-02-27 US disclosed
EP-2616469-A1 INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-07-24 EP disclosed
WO-2012037226-A1 INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140058103-A1 Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture PIK3CD, PIK3CA, PIK3R5 ALDH1A1 3321/4885MAPT 3458/4885KDM4E 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.